The Pharmaceutical and Chemical Journal, 2022, 9(3):1-16

Available online www.tpcj.org

Review Article

ISSN: 2349-7092
CODEN(USA): PCJHBA

A review exploring of cell cycle pathways as potential cancer therapeutic target

Hiral Lal[1], Ankur Sharma[3], Bhumika Dadheech[2], Mangi Lal Choudhary[2]

[1]Research Scholar, Department of pharmacology, Shrinathji institute of pharmacy, Nathdwara 313301
[2]Research Scholar, Department of pharmacology, B.N. College of pharmacy Udaipur, Rajasthan 313001
[3]Assistant Professor, Department of pharmaceutics, Shrinathji institute of pharmacy, Nathdwara 313301
*Corresponding author: Mr. Mangi Lal Choudhary, Research Scholar, Department of pharmacology, B.N. College of pharmacy Udaipur, Rajasthan India: 313301 Email: ashokkumarchoudhary95@gmail.com, Cont. +91 9784455883

Abstract Cancer is defined by means of uncontrolled tumour growth boom precipitated via ordinary cell cycle protein activity. As a result, cell cycle regulators are famous goals in most cancers therapy. Surprisingly, animal studies exhibit that some of these proteins are now not required for non-transformed cell proliferation or tissue growth. Many malignancies, on the other hand, matter on these proteins exclusively and are thus especially inclined to their suppression. Following a long time of research on the physiological roles of cell cycle proteins and their relevance to cancer, the first accepted most cancers remedy targeting a direct regulator of the cell cycle was once recent we listen on proteins that govern cell cycle progression directly (such as cyclin-dependent kinases (CDKs)), as nicely as checkpoint kinases, Aurora kinases, and Polo-like kinases (PLKs). The position of cell cycle proteins in cancer, the purpose for concentrated on them in most cancers' treatment, the outcomes of medical studies, and the future therapeutic workable of more than a few cell cycle inhibitors are all discussed.

Keywords Physiologically, Therapeutically, Individually characterized

Introduction

The mammalian cell cycle is a well-organized and well-regulated process that ensures genetic cloth duplication and cell division. Growth-regulatory signals, as properly as indicators from proteins that screen genetic integrity to ensure the absence of any genetic damage, are all section of this regulation. Proliferation is based on the cell cycle's development thru four wonderful phases — G0/G1, S, G2, and M — which is regulated by means of a couple of cyclin-dependent kinases (CDKs) that work in tandem with their cyclin partners. CDK exercise in cell cycle manage is closely regulated: it is activated by using mitogenic indicators and can be blocked by using cell cycle checkpoint activation in response to DNA injury.

Abnormal cell cycle endeavor is a hallmark of cancer. Mutations in upstream signaling pathways or genetic abnormalities in genes producing cell cycle proteins motive this to happen. The abnormal activation of CDKs, which is frequent in human malignancies, supplied a basis for growing CDK inhibitors as anticancer medicines. The physiological feature of cell cycle proteins, their function in cancer, and how their focused inhibition provides new therapy picks for cancer patients are discussed in this Review. We solely look at CDKs, checkpoint kinases, Aurora kinases, and Polo-like kinases, as nicely as checkpoint kinases, Aurora kinases, and Polo-like kinases (PLKs). This

Review excludes CDKs with transcriptional features and DNA damage response proteins with a hyperlink to cell cycle regulation, such as poly (ADP-ribose) polymerase (PARP).

Cell cycle proteins have an important role to play

Proteins that inhibit cyclin-dependent kinases and their role in cancer

The interplay of cyclin-dependent kinases (CDKs) with cyclin-dependent kinase inhibitors regulates their activity (CKIs). Members of the INK4 household (p16INK4A, p15INK4B, p18INK4C, and p19INK4D) bind to CDK4 and CDK6 and forestall their interplay with D type cyclins, effectively shutting down CDK4 and CDK6 kinase activity. CKIs from the CIP/KIP household (p21CIP1, p27KIP1, and p57KIP2), on the different hand, bind to all cyclin–CDK complexes and largely suppress CDK2 and CDK1 kinase activity. CKIs have tumor-suppressive activities, which is predicted given their role as bad regulators of the cell cycle. In human tumor's genomic deletions, loss of function point mutations, or promoter methylation mute the expression of INK4 proteins, specially p16INK4A and p15INK4B (encoded *via* CDKN2A and CDKN2B, respectively). Furthermore, in human tumor's, p27KIP1 expression is oftentimes down regulated as an end result of extended protein breakdown, an event linked to terrible survival, notwithstanding the fact that deletion of its chromosomal locus (CDKN1B) is uncommon. To look at the function of CKIs in carcinogenesis, many mouse models had been created. Mice missing p16INK4A, for example, fashioned tumor's spontaneously and were extra inclined to carcinogen-induced neoplasia. Similarly, animals lacking p21CIP1 had a higher fee of spontaneous tumors in specific tissues. Intriguingly, mice heterozygous for Cdkn1b (encoding p27KIP1) showed more advantageous carcinogenesis susceptibility after exposure to radiation or chemical carcinogens, however did not lose the remaining wild-type allele, implying a haploinsufficient tumors suppressor role for this CKI46. These findings exhibit that CKIs function as tumors suppressors in general, probable by using limiting uncontrolled CDK endeavor and consequently appearing as a second line of defence against malignant transformation.



Multiple proteins and pathways are involved in the regulation of G1–S and G2–M cell cycle transitions

Others (such as Wnt1 and Myc, which have G12R and A59T mutations) or Erbb2V664E mutations — however now not others (such as G12R and A59T mutations) [18,19]. Further research verified that, at least in the case of Erbb2V664E, the kinase recreation of CDK4 was vital for cyclin D1 feature [20–22]. Ccnd3 knockout mice had

been resistant to lymphoma development brought about by constitutively energetic AKT24, whereas Cdk6 knockout mice were resistant to lymphoma formation produced via NOTCH1ICD-driven T cell acute lymphoblastic leukaemia [23]. Intriguingly, lung most cancers pushed by means of oncogenic KrasG12V confirmed particular sensitivity to CDK4 inhibition, as Cdk4 acute deletion that is, conditional deletion after tumors formation promoted senescence and inhibited tumour progression [25] but no longer Cdk6 or Cdk2. In mice with Erbb2V664E-driven mammary tumor's, acute and world ablation of Ccnd1 or pharmacological inhibition of CDK4/6 kinase endeavor avoided most cancers boom and prompted tumors cell-specific senescence barring having any evident effects on normal, non-transformed tissues [26]. Surprisingly, in mice with Notch1ICD-driven T ALL, acute and accepted deletion of Ccnd3 or suppression of CDK4/6 resulted in tumour cell-specific apoptosis alternatively than senescence, albeit the mechanism for this response has yet to be elucidated [26,27]. Individual D kind cyclins, CDK4 and CDK6, are imperative for tumour start, and their ongoing expression is quintessential for tumour maintenance, in accordance to these studies.

The CDK4–CDK6–RB pathway's biology

Cells in most grownup tissues are in the G0 phase of the cell cycle, which can be transient (quiescence) or permanent (terminal differentiation or senescence). Mitogenic factors can be used to stimulate quiescent cells to enter the cell cycle again. The majority of these elements stimulate intracellular signalling networks that interact with CDK4 and CDK6 to promote cell cycle progression from G0 or G1 to S phase, the place DNA replication takes area. CDK4 and CDK6 are tissue-specific serine/threonine kinases that are very comparable in nature. CDK4 and CDK6 phosphorylate a group of goal proteins that are normally identical [1] In most tissues, gene knockout checks confirmed sizeable functional redundancy between CDK4 and CDK6 in vivo [2]. CDK6 has also been discovered to play sure awesome cyclin-independent transcriptional things to do in haematopoietic cells [3]. Several pathways impact the activation of CDK4 and CDK6 (hence referred to as CDK4/6): binding to CDK inhibitors of the INK4 family (p16INK4A, p15INKB, p18INK4C, and p19INK4D) two and positively via association with D kind cyclins (cyclins D1–3) [4]. Cell cycle development and predominant regulatory proteins are depicted in Figure 1. Mitogenic alerts spark off cyclin-dependent kinases (CDKs), which phosphorylate (P) a variety of cell targets, such as the retinoblastoma protein, to promote progression from the G1 to the S phase (RB). Hyper phosphorylation of RB reduces its growth-suppressive results and permits the E2F household of transcription elements to spark off transcription. Growth-inhibitory alerts up alter CDK inhibitors from the INK4 and CIP/KIP families, which block G1–S progression. Cyclin–CDK complexes, together with other proteins which include Polo-like kinase 1 (PLK1) and Aurora kinases, manipulate progression via S section and from G2 segment into mitosis (M phase) (Aurora A and Aurora B). Cells can probably enter a reversible or everlasting cell cycle arrest by means of exiting the cell cycle (G0 phase). Furthermore, DNA damage is detected via severa specialized proteins and causes cell cycle arrest in the G1 segment by means of checkpoint kinase 2 (CHK2) and p53, or in the S or G2 segment with the aid of CHK1. Positive regulators of cell cycle development are crimson ovals, while terrible regulators of cell cycle development are blue ovals. Dephosphorylation is indicated by using the letter P in the dashed circle.



Cell cycle progression and major regulatory proteins

The cyclin D–CDK4 and cyclin D–CDK6 complexes (hereafter referred to as cyclin D–CDK4/6) promote cell cycle progression in two ways [5]. They first sequester p21CIP1 and p27KIP1, two CDK inhibitors that bind to and block cyclin E–CDK2 kinase activation (BOX 1). Second, active cyclin D–CDK4/6 complexes phosphorylate a variety of cellular targets, the most vital of which are the retinoblastoma tumors suppressor protein (RB, encoded by using RB1) and the intently related proteins p107 (also recognized as RBL1) and p130 (also acknowledged as RBL2), permitting E2F transcription factors to prompt transcription of a range of genes worried in cell cycle development from G1 to S phase, DNA replication (SAC). Cyclins E1 and E2, which bind to and activate CDK2, are E2F transcriptional targets. The Cyclin E–CDK2 complexes phosphorylate RB even further, resulting in a fine comments loop. D type cyclins, CDK4 and CDK6, in addition to these canonical cell cycle roles, have been proven or hypothesized to behavior a range of non-canonical functions, some of which may additionally be relevant for proliferation regulation.

CDK1

CDK1. CDK1 is the solely CDK that is quintessential for cell cycle progression [59]. During G2 phase, CDK1 binds to and becomes activated via cyclin A2 and cyclin B. Upon entry into mitosis, cyclin A2 is degraded and CDK1 recreation is maintained in complexes with B-type cyclins; CDK1 kinase endeavor is required for mitotic entry and numerous mitotic events. B-type cyclins are degraded by using the anaphase-promoting complex/cyclosome (APC/C) in late mitosis [60]. This extinguishes CDK1 undertaking and allows chromosome separation and completion of mitosis and cytokinesis. In addition to law through its cyclin partners, CDK1 recreation is inhibited by way of phosphorylation at Thr14 and Tyr15, mediated by means of the kinases membrane associated tyrosine- and threonine-specific cdc2- inhibitory kinase (MYT1; additionally recognized as PKMYT1) [61] and WEE1 [62], respectively; this phosphorylation is relieved by means of CDC25 phosphatases62.Interestingly, CDK1 activity is

hardly ever deregulated in cancer, one of the few examples being CCNB3 gene amplifications in neuroendocrine prostate cancer [63]. Transgenic overexpression of Ccnb1 or Ccnb2 expanded susceptibility to carcinogen-induced pores and skin and lung tumours, revealing a potential function for increased CDK1 undertaking in tumorigenesis [64]. Moreover, CDK1 has been shown to be required for tumors formation and progression. For example, liver-specific ablation of Cdk1 conferred resistance to NRAS-G12V-induced liver tumorigenesis [65], and CDK1 inhibition blocked the boom of KRAS-mutant (G12V, G12D or G12S) colorectal cancer xenografts [66]. However, CDK1 recreation is critical for proliferation additionally in normal, non-transformed cells [59], arguing towards inhibition of CDK1 as a plausible therapeutic strategy. Intriguingly, inhibition of CDK1 brought about apoptosis of MYC-driven mouse lymphomas and liver tumours [67], as properly as human basal-like triple-negative breast cancer cells [68]. These findings increase a possibility that CDK1 inhibition may particularly kill tumour cells, while inflicting solely transient cell cycle arrest in ordinary tissues, a thought that requires similarly investigation using genetic mouse models. genetic display for genes that manipulate the cell cycle carried out by using Hartwell [11,12]. It is a proline-directed kinase that preferentially phosphorylates the consensus sequence S/T-P-x-K/R (where × is any amino acid), even though it additionally phosphorylates the minimal consensus sequence S/T-P [13], and current work indicates that at least in vitro Cdk1 can additionally phosphorylate non-SP/TP websites [14-16]. Cdk1 substrates often include more than one phosphorylation websites that are clustered in regions of intrinsic disorder, and their genuine role in the protein is regularly poorly conserved in evolution, indicating that specific positioning of phosphorylation is not required for rules of the substrate [17-19]. Cdk1 interacts with 9 distinctive cyclins during the cell cycle. The interaction with cyclins is essential for activation of its kinase endeavor and additionally for recruitment and choice of substrates. For example, numerous cyclins incorporate a hydrophobic patch that binds the RXL (also known as Cy) motif in Cdk1 substrates. This hydrophobic patch is important for substrate determination of some cyclin-Cdk1 complexes, like e.g. Clb5-Cdk1, while for other cyclins it helps decide the cell localization of the cyclin-Cdk1 complex, like e.g. Clb2-Cdk1 [20]. Significant overlap exists between substrates that are phosphorylated by using the more than a few cyclin-Cdk1 complexes [21], because overexpression of a single Clb (e.g. Clb1 [22] or Clb6 [23]) can rescue the lethality of a clb1,2,3,4,5,6 mutant. However, strong cell cycle progression depends on the orderly expression of cyclins [21,24-27], indicating that exclusive cyclin-Cdk1 complexes are essential for phosphorylation of the right proteins at the right time. The fact that aberrant CDK undertaking underpins proliferation of tumor cells makes it a relatively vast lookup problem [28]. Approximately seventy five bona fide in vivo Cdk1 ambitions have been recognized for this reason a ways. However, this quantity is probable to be an underestimate, because a latest study that combined unique chemical inhibition of Cdk1 with quantitative mass spectrometry recognized over 300 manageable Cdk1 aims [17]. In this review we talk about some of the key cell cycle processes from the perspective of Cdk1. Because it is impossible to discuss all these processes and pursuits in detail, we will emphasize just a few of them, while discussing the others in broader terms and referring the reader to lately published reviews and articles for in addition reading.

Regulation of Cdk1

The upstream law of Cdk1 has been extensively reviewed [21,29-31] and consequently we will just supply a greater conventional precis of what is recognized about rules of Cdk1 in budding yeast. Cyclins and CDKs are well conserved between S. cerevisiae and mammals. For instance, human cyclins can replacement for budding yeast cyclins [32], and human Cdc2 (Cdk1 in S. cerevisiae) can replacement for Cdc2 in S. pombe [33] and for Cdk1 in S. cerevisiae [34], illustrating the evolutionary conservation of cell cycle control. Cdk1 is inactive in the course of G1 due to low concentrations of cyclins and the presence of the cyclin dependent kinase inhibitors (CKIs) Sic1 and Far1 [23,35].



Cdk1 and regulation of DNA replication*. During G1 phase of the cell cycle, when Cdk1 is inactive, cells assemble pre-RC complexes onto their origins of replication. When Cdk1 becomes active at the end of G1 phase it phosphorylates several components of the complex, and especially phosphorylation of Sld2 and Sld3 results in origin firing and initiation of DNA replication. After origin firing, several components dissociate and cannot re-assemble into replication-competent origins until they become dephosphorylated and Cdk1 becomes inactivated during G1, thus providing a mechanism for prevention of re-replication.*

Its undertaking will increase at late G1, when cyclin concentrations upward push and the CKIs are degraded [29]. Cdk1 undertaking stays excessive till anaphase, when it drops because cyclins are destroyed and CKIs are re-expressed [23,36]. This drop in Cdk1 exercise is paramount to exit from mitosis (see area 'Cdk1 and exit from mitosis') and it resets the cell cycle to a simple G1 nation of low Cdk1 activity. As will be mentioned later, the fluctuation in Cdk1 endeavor serves necessary features in restricting DNA replication, repair and segregation to precise phases of the cell cycle and ensures irreversibility of the variety of phases of the cell cycle. The most important Cdk1 regulators are discussed below, though many extra proteins can affect Cdk1 activity to a sure extent [29].

CDK2

Cyclin-dependent kinase-2 (CDK2) drives the progression of cells into the S and M phases of the cell cycle. CDK2 undertaking is largely dispensable for everyday development, but it is severely associated with tumor boom in more than one most cancers types. Although the position of CDK2 in tumorigenesis has been controversial, rising evidence proposes that selective CDK2 inhibition may grant therapeutic gain towards positive tumors, and it continues to attraction as a method to exploit in anticancer drug development. Several small-molecule CDK2 inhibitors have advanced to the medical trials. But, a CDK2-selective inhibitor is but to be discovered. Here, we talk about the contemporary understandings of the function of CDK2 in regular and cancer cells, review the core pharmacophores used to target CDK2, and define strategies for the rational plan of CDK2 inhibitors. We attempt to provide an outlook on how CDK2-selective inhibitors might also open new avenues for most cancers therapy. The cell division cycle is an imperative manner in existence the place collection of occasions happens in a cell resulting in the formation of two identical daughter cells [1]. It governs the transition from quiescence or cytokinesis to cell proliferation, and thru its checkpoints, ensures genome stability [2] Cell division cycle entails four sequential phases [3] S phase, when DNA replication occurs, and M phase, when the cell divides into two daughter cells, are separated

by gaps recognised as G1 and G2. In G1, cells undertake most of their increase and synthesize proteins, RNAs and organelles wished for DNA synthesis, whereas in G2 the microtubules that will be used to mobilize the chromosomes in M section are assembled. Quiescence (G0) represents exit from the cell cycle both due to deprivation of mitogen or full differentiation of the cell (e.g., coronary heart muscle cells and neurons) [4]. Most person cells are at G0 and the transcriptional recreation of E2F transcription elements (E2Fs) is repressed by way of the retinoblastoma proteins (hereafter called Rb).4 When needed, these cells can go again into the cell division cycle [5, 6]. Briefly, cells at G0 enter G1 due to mitogenic stimuli. This requires CDK3-cyclin C, which phosphorylates Rb at Ser807/811 [7]. During G1, D-type cyclins bind and set off CDK4 and/or CDK6, additionally ensuing in partial phosphorylation of Rb, main to the activation of E2Fs. At this stage, E2Fs stay sure to Rb, however are capable to transcribe genes such as CCNE1, CCNA2, CCNB1, CDK2 and CDK1. In late G1 (after the restriction point) cyclin E binds to CDK2 to in addition phosphorylate Rb, releasing and totally activating the E2Fs. E2Fs then set off the transcription of S section proteins such as cyclins A and E [4-6]. CDK2-cyclin A, CDK1-cyclin A and CDK1-cyclin B then preserve the phosphorylation of Rb making sure cell cycle progression. CDK2-cyclin A enables S/G2 transition, and CDK1-cyclin A and CDK1-cyclin B allow the graduation of mitosis and the development through M phase, respectively. Finally, cyclin B is degraded, and Rb is dephosphorylated via two phosphatases, PP1 and PP2A, returning the cell to G1 state [5, 6, 8]. Intriguingly, animal models have established that CDK2, CDK4 and CDK6 (interphase CDKs) or their cyclin counterparts are no longer quintessential for proliferation of non-transformed cells and development of most tissues [9]. On the other hand, deregulation of CDKs has been reported to cause unscheduled proliferation, genomic and chromosomal instability resulting in human cancer, and to make a contribution to each cancer progression and aggressiveness [10]. Additionally, many cancers are uniquely established on CDKs and therefore are selectively touchy to their inhibition [11]. In this regard, the most profitable medical strategy to date has worried focused on CDK4 and CDK6 the place three CDK4/6-selective inhibitors, namely palbociclib, abemaciclib and ribociclib are accepted for therapy of breast cancer. There are countless amazing opinions on the CDK region that consist of some factors of CDK2 [13-16]. But, an updated assessment comprising the biology of CDK2 and the medicinal chemistry of its inhibitors in conjunction with techniques for designing of CDK2-selective inhibitors is lacking. Thus, this evaluation focuses on the position of CDK2 in non-transformed and most cancers cells, the reason for growing CDK2-targeted most cancers therapy, as well as on the layout and future therapeutic viable of CDK2-selective inhibitors in most cancers treatment. cells, DNA replicates in S phase, and chromosome segregation occurs at M phase. Two gap phases separate S segment and M phase: G1 when cells grow and synthesize proteins, and G2 when cells prepare for mitosis. CDK3-cyclin C stimulates Rb phosphorylation to effect G0/G1 transition. CDK4/6-cyclin D and CDK2-cyclin E mediated sequential phosphorylation of Rb relieves suppression of the exercise of the E2Fs permitting G1/S transition through the restriction point. As cells prepare to exit from S phase, CDK2-cyclin A directly phosphorylates E2F to deactivate its characteristic stopping apoptosis that may be prompted by way of persistent E2F activity. CDK1 in complex with cyclin A or B has defined roles in regulating the G2/M checkpoint and development through mitosis. The cell cycle is controlled by checkpoints. The integrity of the DNA is assessed at the G1/S checkpoint. Proper chromosome replication is checked at the S and G2/M checkpoints. Attachment of each sister chromatids to a spindle fiber is evaluated at the spindle assembly checkpoint (SAC).

Structure and Regulation

Constituting an important phase of phosphotransferases in the human genome, kinases catalyze the reversible switch of the γ-phosphate crew of ATP onto a target substrate, mediate signal transductions and regulate most components of cell life [17]. Currently, about 518 human protein and 20 lipid kinases have been identified. Protein kinases are enzymes that play key regulatory roles in nearly each and every aspect of cell biology, and based upon the nature of the goal amino acid in their substrates, they are categorized as tyrosine kinases, serine/threonine kinases, dual specificity kinases (act as both tyrosine and serine/threonine kinases), and histidine kinases. The phosphorylation of Ser, Thr, or Tyr residues of proteins through kinases consequences in conformational trade altering the pastime of the protein substrates [18]. CDKs belong to the serine/threonine protein kinase household and their kinase exercise

requires binding to a cyclin protein [19]. They are involved in more than a few factors of cell biology exceptionally in cell cycle manipulate (CDKs 1, 2, 3, 4 and 6, see above), transcription (CDKs 7, 8, 9, 12 and 13) rules thru phosphorylation of C-terminal tail of RNA polymerase II, metabolism (CDKs 1, 2, 3, four and 6), [20] and in positive cell types, differentiation (CDKs 1, 2 and 4) [21]. Although CDKs are normally grouped into cell-cycle or transcriptional CDKs, these roles are often mixed in many CDKs.19 CDK7 indirectly regulates the cell cycle with the aid of activating CDKs 1, 2, four and 6. CDKs 5, 10, 11, 14–18 and 20 have heterogeneous and special functions that are regularly tissue specific. For example, CDK5 has a pivotal role in modulating the migration of post-mitotic neurons [22]. CDK10 is implicated in regulating gene transcription with the aid of steroid hormones by using promotion the interplay between heat-shock proteins and the ecdysone receptor EcRB1 [23]. CDK11-cyclin L regulates RNA splicing [24]. Among CDKs, sequence and structure similarity is excessive. For instance, there is 74% sequence identification between CDK2 and CDK3, while root-mean-square deviation of Cα atoms ranges from 1.7 Å for CDK4 to 0.9 Å for CDK5 [25]. In addition, their convergence to a conserved structure upon activation has presented challenges for the plan of selective inhibitors [26]. Yet, the accessible structural variety and conformational plasticity of the CDK fold have been effectively exploited to pleasant tune potency and selectivity and to pick out the first CDK inhibitors to be registered for scientific use concentrated on CDK4 and CDK6. However, most inhibitors nonetheless show off big exercise for a subset of the family [27].



Structural basis of CDK2 activation and inhibition.

CDK2, comparable to different protein kinases, has the traditional bilobal architecture, N-terminal lobe (residues 1-82) and the C-terminal domain (residues 83-297) [18, 19, 28, 29]. The smaller N-terminal lobe is commonly made up of β-sheets (five anti-parallel β-strands) with one αC-helix (PSTAIRE). The αC-helix includes the sequence PSTAIRE, and is indispensable for cyclin binding. The large C-terminal lobe is prosperous in α-helices, and

includes the activation section (also acknowledged as the T-loop (residues 145(Asp)-172(Glu)) and the activating phosphorylation site Thr160. The T-loop is the platform for binding of the Ser/Thr (phosphor-acceptor) area of substrates for phosphorylation. The N-terminal and C-terminal lobes are related through the bendy hinge vicinity (residues 81(Glu)-84(His)), which lines a deep cleft, the ATP-binding site. ATP cognizance involves residues from each lobes. CDK2 affords adjacent binding sites for ATP and the phospho-acceptor protein substrate so that the γ-phosphate of ATP faces the hydroxylated facet chain of Ser/Thr on the substrate surface. Extensive biochemical and structural studies have hooked up a clear photo of the activation and regulatory mechanisms that determine the endeavor of CDK2 [18, 19, 29]. In the absence of mitogenic signals, CDK2 is in an inactive form. During late G1 phase, CDK2 exercise increases as a end result of (1) E2F-mediated transcription of CCNE genes, the protein product of which binds and activates CDK2, (2) CDK4/6-cyclin D-mediated sequestration of the CDK-interacting protein/kinase inhibitory protein (Cip/Kip) type of CDK inhibitors, p21Cip1, p27Kip1 and p57Kip2, which bind to CDK2-cyclin complexes and render them inactive, and (3) due to ubiquitin-mediated proteolysis of Cip/Kip following their phosphorylation with the aid of CDK2 [18, 19, 29]. The Cip/Kip family of inhibitors alternate the shape of the catalytic cleft of CDK2 to completely deactivate the enzyme by way of inserting a small helix interior the catalytic unit in away comparable to ATP. Cyclins E and A regulate CDK2 pastime via being synthesized and destroyed in cell cycle phase-specific manner [18, 19, 29]. The Skp/Cullin/F-box containing complex (SCF) mediates the fast proteasomal degradation of cyclin E throughout S phase and CDK2 buddies with newly synthesized cyclin A to structure energetic CDK2- cyclin A complexes. Cyclin A is secure at some point of interphase, and is degraded via the anaphase promoting complex/cyclosome (APC/C) ubiquitination just before the metaphase to anaphase transition [18, 19, 29]. Once cyclin A is disassociated or degraded, dephosphorylation of Thr160 (see below) is done by a Ser/Thr-directed phosphatase, CDK-interacting phosphatase (KAP) [30]. Cyclins E and A in concert with phosphorylation with the aid of CDK-activating kinase (CAK, CDK7-cyclin H-MAT1 complex) play a crucial role in the rules of CDK2 (Figure 2D) [28, 29]. Although cyclin-binding by myself confers enzymatic recreation on an intrinsically inert CDK2 monomer, T-loop phosphorylation consequences in ∼300-fold make bigger of undertaking in the direction of a substrate [31, 32]. Upon binding to its cyclin partner, CDK2 changes its conformation (Figure 2B) [28, 29]. Extensive hydrophobic interactions between CDK2 and its cyclin associate cross the αC-helix on the N-lobe in the direction of the catalytic cleft. This conformational alternate strikes the facet chain of Glu51 of the αC-helix into an internal position favoring a hydrogen bond between Glu51 and Lys33 allowing Lys33 to bind to the α- and β-phosphates of ATP and align them to allow the phospho-transfer reaction of the γ phosphate to substrate proteins [29]. Additionally, cyclin binding relieves the obstruction at the entrance of the energetic site by means of transferring the T-loop via 20 Å towards the cyclin and displacing onto the C-terminal lobe, leaving the ATP binding web site reachable to substrates [28, 29]. Moreover, cyclin binding was previously concept to be required to expose the buried Thr160 of monomeric CDK2 for phosphorylation by CAK, and this phosphorylation was once believed to lead to further conformational adjustments in the substrate binding web site of CDK2 for the full activation of CDK2- cyclin complex [28, 29]. However, CAK efficiently phosphorylates monomeric CDK2 [31, 32]. During the S-phase of the cell cycle, in order to surpass the opposition for cyclin A from the greater abundant CDK1, Thr160 phosphorylation of CDK2 precedes cyclin A-binding. This is due to the fact of CAK's lack of ability to phosphorylate monomeric CDK1 contributing to a kinetic barrier stopping CDK1-cyclin A assembly. Phosphorylation of the glycine-rich loop (residues 11(Glu)- 18(Tyr)) residues Thr14 and Tyr15 by way of Wee1 and Myt1 kinases, respectively, which can be reversed via the cell division cycle 25 (Cdc25) phosphatases (Cdc25A, Cdc25B and Cdc25C) turns off CDK2 recreation [17, 28, 29].

CDK4/6

Dysregulated cell division, resulting in aberrant cell proliferation, is one of the key hallmarks of cancer, and figuring out therapeutic objectives to block cell division is a widely used approach to most cancers treatment. For a cell to divide, it ought to first growth through a predeter mined range of stages, which are below the control of a complicated network of regulatory factors, termed the cell cycle — a method that is particularly conserved among eukaryotes [1]. Each stage of the cell cycle should be passed via in turn, with strict manipulate over completion of

all the essential procedures exercised at signaling check points, consequently precluding progression in the presence of, for example, genetic harm to the cell. Transition from one stage of the cell cycle to the next is managed via the actions of cyclin-dependent kinases (CDKs), which are activated upon interplay with their companion cyclins. CDKs have, therefore, long been regarded as promising goals for most cancers therapies, though many of the early, first-generation CDK inhibitors failed in clinical development [3,4] at least in phase because nonselective pan-CDK inhibition used to be determined to be poisonous to noncancer cells .These troubles of effectiveness and toxicity appear to have been overcome by means of more selective concentrated on of CDKs four and 6, a pair of kinases that are comparable in structure and function, which mediate transition from G0/G1-phase to S-phase of the cell cycle. Three of these new CDK4/6 inhibitors — abemaciclib, palbociclib and ribociclib — have emerged, following the findings of early phase trials [6–17] as dealers with promising anticancer activity and manageable toxicity; section III trials are currently in progress for each drug. Of these agents, palbociclib has improved furthest towards the clinic, having obtained accelerated approval from the FDA in February 2015, with pivotal segment III records available, in the putting of hormone receptor. (HR)-positive, advanced-stage breast most cancers — a ailment in which signalling of the cyclin D–CDK4 axis is recognised to be critical [6,18,19]. Further work is required to facilitate greatest choice of patients and to handle the inevitable emergence of resistance in the metastatic setting. In this Review, we talk about the organic motive for focused on CDK4/6, evaluation the handy scientific evidence for the sellers that are furthest advanced in development, and talk about the challenges with regard to optimizing their use.

Targeting CDK4/6 in cancer CDK4/6 and G1–S-phase transition

The cell cycle is regulated by using the interaction of cyclins with their accomplice serine/threonine CDKs. The significance of CDKs to the cell cycle was first elucidated through the discovery of cdc28 and cdc2 (homologues of CDK1 in humans) in budding and fission yeast, respectively [20,21] with the unique interacting cyclins described a decade later [22,23]. A in addition 10 years passed earlier than the homologues of cdc28/cdc2 had been proven as being present in different mammalian structures and for the cyclin–CDK nomenclature to be adopted [24,25]. To enter the cell cycle, a cell must development from G1 to S segment through this limit point, a transition that is in part ruled by way of the retinoblastoma-associated protein (RB1) and is normally regulated via perturbations in a refined balance between promitotic and antimitotic signals. Mitogenic signalling is quintessential for entry into the everyday cell cycle, even though its importance is radically decreased as soon as the cell has entered the S phase [26]. According to the traditional view of the initiation of the cell cycle, the D-type cyclins, cyclins D1, D2 and D3, are the key drivers of G1-to-S-phase transition [27–30]. The expression degree of the D-type cyclins is managed through boom issue signalling, with transcription, turnover and nuclear transport of these proteins all based on mitogenic signalling [31–33]. Early in the G1 segment of the cell cycle, a standard promitotic signalling stability consequences in expanded expression of the D-type cyclins, which complicated with, and set off CDK4/6. This complicated as a result phosphorylates RB1, and the other RB1-like, ‘pocket’ proteins p130 and p107 (also regarded as retinoblastoma-like proteins 1 and 2, respectively), at a range of positions [34–36]. In its hypophosphorylated state, RB1 represses the transcription of genes that are fundamental for cell-cycle development via binding to the transactivation domain of the E2F transcription component family of proteins [37–40]; thus, growing phosphorylation of RB1 by the cyclin D–CDK4 complicated reduces inhibitory control of the E2F transcription component household by using RB1. This reduced inhibition of E2F transcription elements initiates a high-quality feedback loop, as the E2F transcription elements promote transcription of the E-type cyclins, which prompt CDK2 and other proteins that are vital for initiation of S segment and DNA synthesis [41,42]. Cyclin E–CDK2 similarly phosphorylates RB1, lowering E2F inhibition and merchandising S-phase entry. During S phase, CDK2 complexes with cyclin A and mediates transcriptional manipulate of DNA synthesis [43–45]. Throughout the system of development thru S phase and G2 phase of the cell cycle, RB1 stays hyperphosphorylated, returning to its hypophosphorylated kingdom solely following mitosis [46–48]. Regulation of the E2F household of transcription factors remains the best-described mechanism via which RB1 exerts manage over the cell cycle; however, other mechanisms are also probable to exist due to the fact RB1 interacts with extra than 100 other proteins, and most of

these interactions are presently poorly understood [49]. Furthermore, proof exists that RB1 exerts transcriptional manipulate via chromatin remodelling; phosphorylation of RB1 leads to a weakening of its interaction with histone deacetylases and modulates cyclin E and cyclin A transcription through the formation of regulatory complexes between RB1 and SWI/SNF chromatin-remodelling proteins [50,51].Members of the inhibitor of CDK4 (INK4) and cyclindependent kinase inhibitor 1/kinase inhibitory protein (CIP/KIP) protein households also alter and manipulate cyclin D–CDK4/6 activity, and are known at the same time as the cyclin-dependent kinase inhibitors (CKIs) [31]. The INK4 group consists of four structurally-related proteins, p16INK4A, p15INK4B, p18INK4C and p19INK4D, which specifically bind to CDK4 and CDK6 and have constrained affinity for different CDKs [52–55]. Of the INK4 group, p1616INK4A is the high-quality described and its expression is brought on by means of a quantity of cell processes, such as oncogenic signalling, senescence, remodeling growth factor-β (TGFβ) signalling, and contact inhibition [56–58]. Increased expression of p1616INK4A is a hallmark of tumours in which RB1 characteristic has been lost [59–62]. The CIP/KIP family is comprised of three proteins, the ubiquitously expressed p27KIP1 and p21CIP1, and a 1/3 member, p57KIP2, which is expressed in a constrained wide variety of tissues [63–68]. In distinction to the members of the INK4 family, the CIP/KIP proteins are in a position to bind to all of the CDKs involved in the cell cycle to varying degrees, and can have both a high-quality and terrible regulatory role depending on the proteins that are complexed. The manipulate of G1-to-S-phase transition exerted by these two businesses of proteins is complicated and interlinked, incorporating a variety of feedback loops. p16INK4A is the best-known inhibitor of cyclin D–CDK4, and contributes to G1 arrest in two ways. Firstly, to become functional, CDK4 requires cytoplasmic, post-translational folding in a complex involving heat shock protein (HSP) 90, an interplay that is disrupted by using p16INK4A [69–71]. In addition, p1616INK4A can bind to CDK4 at once and inhibit its catalytic activity [52,71]. The mixture of these two mechanisms results in G1 arrest in cells with practical RB1, however no longer in RB1-deficient cells [72]. By contrast, the CIP/KIP proteins p21CIP1 and p27KIP1 can stabilize the formation of cyclin D–CDK4 complexes, hence sequestering these proteins and facilitating the activation of CDK2 [73–77].

Non-classical CDK4/6 and G1–S transition

According to the traditional view of G1-to-S-phase transition, cyclin D and CDK4/6 are the key initiators, with the exercise of CDK2 relying on prior activation of CDK4/6. However, doubts over this view of G1-to-S-phase transition had been raised with the aid of the findings of experiments carried out the use of cdk4 and cdk6 knockout mouse models. cdk4-deficient mice had been viable, but small in size, with reproductive and endocrine dysfunction [78–80]. Similarly, cdk6-deficient mice were also viable, but with hypocellularity in the thymus and spleen, and with a small discount in the abundance of peripheral blood cells [81]. The lack of phenotypes with more-severe consequences for survival in these single-knockout mice used to be assumed to mirror practical compensation between cdk4 and cdk6. Surprisingly, even though cdk4/cdk6 double knockout mice succumbed to anaemia in the late levels of embryonic development, many non-haematological cell kinds from these mice had been in a position to proliferate normally [8]. In addition, embryonic fibroblasts except cdk4 and cdk6 could enter S phase, even though with reduced efficiency, with evidence indicating that D-type cyclins can have interaction with cdk2 to pressure cell-cycle transition [81]. Experimental records from mouse fashions would possibly be confined in predicting CDK dependency in human cells; however, the phenotype of the cdk4/6 knockout mouse predicted, with a excessive degree of accuracy, the toxicity profile viewed with first-generation selective CDK4/6 inhibitors in human patients [6,10–13]. The structure of the classical view of the cell cycle, with the limit factor at the G1–S transition, has additionally been challenged with the aid of the demonstration that CDK2 recreation may persist immediately after mitosis, with premitotic degrees of CDK2 and p21CIP1 recreation predicting whether postmitotic daughter cells continue to development through the cycle or emerge as quiescent [82]. Despite caveats in extrapolating experimental facts from murine and in vitro models to human patients, records point out that the classical view of cell-cycle entry, with the necessary function of CDK4/6, is likely overly easy in many cell types. As properly as CDK4/6, other CDKs can also initiate entry to the cell cycle, owing to redundancy in characteristic between exclusive CDKs [83,84] and as such, CDK4/6 is potentially redundant in some cells. The genuine

mechanisms that underlie this redundancy amongst the CDKs have been incompletely described, even though binding of cyclin D1 to CDK2 [81,85] and dysregulation of CCNE1 (the gene that encodes cyclin E) expression may all make contributions. CDK3 can also make a contribution to cell-cycle entry by phosphorylating RB1 throughout the G0-to-G1 transition [86].



***Classical and non-classical models of the cell cycle in RB1-proficient cells. a** | Resting cells in the G0 or early G1 phase. The retinoblastoma protein, RB1, is hypophosphorylated and inhibits the transcriptional activity of the E2F family of proteins. The INK4 protein p16, acts as a brake on the activation of cyclin-dependant kinase (CDK) 4 and/or CDK6. 6. **b** | The classical model of G1–S-phase transition. Mitogenic and oestrogen receptor signalling upregulates the transcription of the D-type cyclins. These D-type cyclins form a complex with CDK4/6 to phosphorylate RB1, thus partially activating the E2F-family proteins, which results in transcription of cyclins A and E, and CDK2. The phosphorylation of RB1 also induces chromatin remodelling that favours transcription (not shown). CDK4/6–cyclin D complexes sequester CDK inhibitor 1/kinase inhibitory protein (CIP/KIP) proteins, reducing their inhibitory effect on CDK2, and reducing the threshold for activation of CDK2 by E-type cyclins. As cyclin E levels rise, cyclin E complexes with CDK2 to hyperphosphorylate RB1, forming a positive feedback loop via E2F, releasing and fully activating E2F, to push the cell from G1 to S phase. **c** | The non-classical model of G1–S-phase transition. CDK2 is active in early G1, by forming complexes with cyclins E and potentially cyclin D directly. Both CDK4/6 and CDK2 phosphorylate RB1, and drive G1–S-phase transition. The mechanisms through which CDK2 becomes active in G1 without requiring prior CDK4/6 activation are poorly understood, although in some rapidly proliferative cells CDK2 remains active immediately after mitosis. CKI; cyclin-dependent kinase inhibitor.*

Conclusions

Although basic cell cycle regulators were discovered more than 30 years ago, our understanding of their function in cancer and their potential as cancer therapy targets has increased dramatically in the last decade. Cell cycle research has moved from the laboratory to the bedside thanks to the introduction of new drugs. The FDA's preliminary approval of palbociclib, a CDK4/6-selective inhibitor, for breast cancer treatment is the first effective clinical

translation in this sector. Other CDK4/6-selective inhibitors have shown promising outcomes, and FDA approval is likely in the next years. Inhibitors that inhibit CDK4 but not CDK6 (and vice versa) may also be produced, with the potential to decrease side effects while maintaining therapeutic effectiveness. Furthermore, CDK2- and CDK1-selective inhibitors are available.

References

[1]. Anders, L. et al. A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 20, 620–634 (2011).
[2]. Malumbres, M. & Barbacid, M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9, 153–166 (2009).
[3]. Kollmann, K. et al. A new kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell 24, 167–181 (2013). \
[4]. Malumbres, M. & Barbacid, M. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer 1, 222–231 (2001).
[5]. Sherr, C. J. & Roberts, J. M. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 18, 2699–2711 (2004).
[6]. Hydbring, P., Malumbres, M. & Sicinski, P. Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases. Nat. Rev. Mol. Cell Biol. 17, 280–292 (2016).
[7]. Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899–905 (2010).
[8]. Schmidt, E. E., Ichimura, K., Reifenberger, G. & Collins, V. P. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res. 54, 6321–6324 (1994).
[9]. Wölfel, T. et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269, 1281–1284 (1995).
[10]. Corcoran, M. M. et al. Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations. Oncogene 18, 6271–6277 (1999).
[11]. Sotillo, R. et al. Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J. 20, 6637–6647 (2001).
[12]. Sotillo, R. et al. Invasive melanoma in Cdk4-targeted mice. Proc. Natl Acad. Sci. USA 98, 13312–13317 (2001).
[13]. Wang, T. C. et al. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369, 669–671 (1994).
[14]. Rojas, P. et al. Cyclin D2 and cyclin D3 play opposite roles in mouse skin carcinogenesis. Oncogene 26, 1723–1730 (2007).
[15]. Wang, X., Sistrunk, C. & Rodriguez-Puebla, M. L. Unexpected reduction of skin tumorigenesis on expression of cyclin-dependent kinase 6 in mouse epidermis. Am. J. Pathol. 178, 345–354 (2011).
[16]. Yamamoto, H. et al. Enhanced skin carcinogenesis in cyclin D1-conditional transgenic mice: cyclin D1 alters keratinocyte response to calcium-induced terminal differentiation. Cancer Res. 62, 1641–1647 (2002).
[17]. Miliani de Marval, P. L., Macias, E., Conti, C. J. & Rodriguez-Puebla, M. L. Enhanced malignant tumorigenesis in Cdk4 transgenic mice. Oncogene 23, 1863–1873 (2004).
[18]. Yu, Q., Geng, Y. & Sicinski, P. Specific protection against breast cancers by cyclin D1 ablation. Nature 411, 1017–1021 (2001). The first study to demonstrate the oncogene-dependent requirement for cyclin D1 in mammary tumorigenesis in vivo using mouse cancer models.
[19]. Bowe, D. B., Kenney, N. J., Adereth, Y. & Maroulakou, I. G. Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E. Oncogene 21, 291–298 (2002).
[20]. Yu, Q. et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 9, 23–32 (2006).

[21]. Reddy, H. K. et al. Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis. Cancer Res. 65, 10174–10178 (2005).

[22]. Landis, M. W., Pawlyk, B. S., Li, T., Sicinski, P. & Hinds, P. W. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 9, 13–22 (2006). References 20–22 demonstrated the requirement for CDK4 kinase activity in mammary tumorigenesis using mouse cancer models, indicating the potential value of inhibiting CDK4 in breast cancer therapy.

[23]. Sicinska, E. et al. Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell 4, 451–461 (2003).

[24]. Hu, M. G. et al. A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis. Cancer Res. 69, 810–818 (2009). This work showed that mice lacking CDK6 are resistant to lymphoma formation induced by v-AKT and therefore suggested that CDK6-selective inhibitors may be used to treat lymphoid malignancies.

[25]. Puyol, M. et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18, 63–73 (2010). This seminal work provided evidence for the dependence of KRAS-G12V-induced mouse lung cancers on the activity of CDK4 not only for tumour initiation but also during tumour progression, using an acute genetic shutdown of Cdk4 or inhibition of CDK4/6 kinase activity in tumour-bearing mice.

[26]. Choi, Y. J. et al. The requirement for cyclin D function in tumor maintenance. Cancer Cell 22, 438–451 (2012). This study validated cyclins D1 and D3 and their associated kinases as suitable therapeutic targets in mammary cancer and T-ALL, respectively, by using acute and ubiquitous genetic shutdown as well as CDK4/6-selective inhibitors in tumour-bearing mice.

[27]. Sawai, C. M. et al. Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia. Cancer Cell 22, 452–465 (2012).

[28]. Watanabe, N., Broome, M. & Hunter, T. Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle. EMBO J. 14, 1878–1891 (1995).

[29]. Ma, T. et al. Cell cycle-regulated phosphorylation of p220NPAT by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription. Genes Dev. 14, 2298–2313 (2000).

[30]. Okuda, M. et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 103, 127–140 (2000).

[31]. Strohmaier, H. et al. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 413, 316–322 (2001).

[32]. Koepp, D. M. et al. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 294, 173–177 (2001).

[33]. Scaltriti, M. et al. Cyclin E amplification/ overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc. Natl Acad. Sci. USA 108, 3761–3766 (2011).

[34]. Etemadmoghadam, D. et al. Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc. Natl Acad. Sci. USA 110, 19489–19494 (2013).

[35]. Spruck, C. H. et al. hCDC4 gene mutations in endometrial cancer. Cancer Res. 62, 4535–4539 (2002).

[36]. Kemp, Z. et al. CDC4 mutations occur in a subset of colorectal cancers but are not predicted to cause loss of function and are not associated with chromosomal instability. Cancer Res. 65, 11361–11366 (2005).

[37]. Akli, S., Van Pelt, C. S., Bui, T., Meijer, L. & Keyomarsi, K. Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E. Cancer Res. 71, 3377–3386 (2011).

[38]. Chao, Y. et al. Overexpression of cyclin A but not Skp 2 correlates with the tumor relapse of human hepatocellular carcinoma. Cancer Res. 58, 985–990 (1998).

[39]. Handa, K., Yamakawa, M., Takeda, H., Kimura, S. & Takahashi, T. Expression of cell cycle markers in colorectal carcinoma: superiority of cyclin A as an indicator of poor prognosis. Int. J. Cancer 84, 225–233 (1999).

[40]. Michalides, R. et al. Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br. J. Cancer 86, 402–408 (2002).
[41]. Gstaiger, M. et al. Skp2 is oncogenic and overexpressed in human cancers. Proc. Natl Acad. Sci. USA 98, 5043–5048 (2001).
[42]. Galaktionov, K. et al. CDC25 phosphatases as potential human oncogenes. Science 269, 1575–1577 (1995).
[43]. Takemasa, I. et al. Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma. Cancer Res. 60, 3043–3050 (2000).
[44]. Broggini, M. et al. Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. Anticancer Res. 20, 4835–4840 (2000).
[45]. Bortner, D. M. & Rosenberg, M. P. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol. Cell. Biol. 17, 453–459 (1997).
[46]. Fero, M. L., Randel, E., Gurley, K. E., Roberts, J. M. & Kemp, C. J. The murine gene p27Kip1 is haploinsufficient for tumour suppression. Nature 396, 177–180 (1998).
[47]. Martin-Caballero, J., Flores, J. M., Garcia-Palencia, P. & Serrano, M. Tumor susceptibility of p21Waf1/Cip1- deficient mice. Cancer Res. 61, 6234–6238 (2001).
[48]. Yao, Y. et al. Increased susceptibility to carcinogeninduced mammary tumors in MMTV-Cdc25B transgenic mice. Oncogene 18, 5159–5166 (1999).
[49]. Ray, D. et al. Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability. Cancer Res. 67, 984–991 (2007).
[50]. Ray, D. et al. Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice. Cancer Res. 67, 6605–6611 (2007).
[51]. Tetsu, O. & McCormick, F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 3, 233–245 (2003).
[52]. Padmakumar, V. C., Aleem, E., Berthet, C., Hilton, M. B. & Kaldis, P. Cdk2 and Cdk4 activities are dispensable for tumorigenesis caused by the loss of p53. Mol. Cell. Biol. 29, 2582–2593 (2009).
[53]. Macias, E., Kim, Y., Miliani de Marval, P. L., Klein-Szanto, A. & Rodriguez-Puebla, M. L. Cdk2 deficiency decreases ras/CDK4-dependent malignant progression, but not myc-induced tumorigenesis. Cancer Res. 67, 9713–9720 (2007).
[54]. Gillam, M. P. et al. MEN1 tumorigenesis in the pituitary and pancreatic islet requires Cdk4 but not Cdk2. Oncogene 34, 932–938 (2015).
[55]. Campaner, S. et al. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat. Cell Biol. 12, 54–59 (2010).
[56]. Hydbring, P. et al. Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation. Proc. Natl Acad. Sci. USA 107, 58–63 (2010).
[57]. Du, J. et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 6, 565–576 (2004).
[58]. Ray, D., Terao, Y., Christov, K., Kaldis, P. & Kiyokawa, H. Cdk2-null mice are resistant to ErbB-2-induced mammary tumorigenesis. Neoplasia 13, 439–444 (2011).
[59]. Santamaria, D. et al. Cdk1 is sufficient to drive the mammalian cell cycle. Nature 448, 811–815 (2007).
[60]. Gavet, O. & Pines, J. Progressive activation of cyclinB1–Cdk1 coordinates entry to mitosis. Dev. Cell 18, 533–543 (2010).
[61]. Mueller, P. R., Coleman, T. R., Kumagai, A. & Dunphy, W. G. Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science 270, 86–90 (1995).
[62]. Parker, L. L. & Piwnica-Worms, H. Inactivation of the p34cdc2–cyclin B complex by the human WEE1 tyrosine kinase. Science 257, 1955–1957 (1992).
[63]. Beltran, H. et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat. Med. 22, 298–305 (2016).

[64]. Nam, H. J. & van Deursen, J. M. Cyclin B2 and p53 control proper timing of centrosome separation. Nat. Cell Biol. 16, 538–549 (2014).
[65]. Diril, M. K. et al. Cyclin-dependent kinase 1 (Cdk1) is essential for cell division and suppression of DNA re-replication but not for liver regeneration. Proc. Natl Acad. Sci. USA 109, 3826–3831 (2012).
[66]. Costa-Cabral, S. et al. CDK1 is a synthetic lethal target for KRAS mutant tumours. PLoS ONE 11, e0149099 (2016).
[67]. Goga, A., Yang, D., Tward, A. D., Morgan, D. O. & Bishop, J. M. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat. Med. 13, 820–827 (2007).
[68]. Horiuchi, D. et al. MYC pathway activation in triplenegative breast cancer is synthetic lethal with CDK inhibition. J. Exp. Med. 209, 679–696 (2012). References 67 and 68 introduced the potential therapeutic value of CDK1-selective inhibitors for targeting MYC-overexpressing tumours such as triple-negative breast cancers.
[69]. Zhao, H. & Piwnica-Worms, H. ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol. Cell. Biol. 21, 4129–4139 (2001).
[70]. Matsuoka, S. et al. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc. Natl Acad. Sci. USA 97, 10389–10394 (2000).
[71]. El-Deiry, W. S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817–825 (1993).
[72]. Sanchez, Y. et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277, 1497–1501 (1997).
[73]. Peng, C. Y. et al. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277, 1501–1505 (1997).
[74]. O'Connell, M. J., Raleigh, J. M., Verkade, H. M. & Nurse, P. Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation. EMBO J. 16, 545–554 (1997).
[75]. Mu, K. et al. Detection of CHK1 and CCND1 gene copy number changes in breast cancer with dual-colour fluorescence in-situ hybridization. Histopathology 58, 601–607 (2011).
[76]. Menoyo, A. et al. Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability. Cancer Res. 61, 7727–7730 (2001).
[77]. Liu, Q. et al. Chk1 is an essential kinase that is regulated by Atr and required for the G2/M DNA damage checkpoint. Genes Dev. 14, 1448–1459 (2000).
[78]. Fishler, T. et al. Genetic instability and mammary tumor formation in mice carrying mammary-specific disruption of Chk1 and p53. Oncogene 29, 4007–4017 (2010).
[79]. Tho, L. M., Libertini, S., Rampling, R., Sansom, O. & Gillespie, D. A. Chk1 is essential for chemical carcinogen-induced mouse skin tumorigenesis. Oncogene 31, 1366–1375 (2012).
[80]. Xu, J. et al. Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. Oncogene 32, 976–987 (2013).
[81]. Verlinden, L. et al. The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor / progesterone receptor /HER-2 breast carcinomas. Cancer Res. 67, 6574–6581 (2007).
[82]. Xie, Y. et al. Checkpoint kinase 1 is negatively regulated by miR-497 in hepatocellular carcinoma. Med. Oncol. 31, 844 (2014).
[83]. Lopez-Contreras, A. J., Gutierrez-Martinez, P., Specks, J., Rodrigo-Perez, S. & FernandezCapetillo, O. An extra allele of Chk1 limits oncogeneinduced replicative stress and promotes transformation. J. Exp. Med. 209, 455–461 (2012).
[84]. Masaki, T. et al. Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology 37, 534–543 (2003).
[85]. Mir, S. E. et al. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 18, 244–257 (2010).
[86]. Magnussen, G. I. et al. High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy. PLoS ONE 7, e38254 (2012).